Ann S. LaCasce, MD

Ann S. LaCasce, MD, assistant professor of medicine, Harvard Medical School, lymphoma program, Dana-Farber Cancer Institute, discusses the combination of brentuximab vedotin and bendamustine for the treatment of patients with Hodgkin lymphoma.

The study analyzed 53 patients with Hodgkin lymphoma who were in first relapse or had primary refractory disease after initial therapy.

Patients were treated with brentuximab vedotin in combination with bendamustine.

83% of patients achieved a complete remission.

Some unexpected infusion-related toxicity was observed.

Articles

Ann S. LaCasce, MD, discusses the combination of brentuximab vedotin and bendamustine for the treatment of patients with Hodgkin lymphoma.

Ann S. LaCasce, MD | Authors

Articles

Brentuximab Vedotin in Combination With Bendamustine for Patients With Hodgkin Lymphoma